首頁 > 市場調查報告書 > 製藥

以基因為基之藥物開發生物標記

市場調查報告書

商品編碼

2107868

基因生物標記市場：按適應症、最終用戶和地區分類

Genomic Biomarker Market, By Indication, By End User, By Geography

出版日期: 2026年07月01日 | 出版商:

Coherent Market Insights | 英文 259 Pages | 商品交期: 2-3個工作天內

價格

簡介目錄

基因生物標記市場預計到 2026 年將達到 69 億美元，到 2033 年將達到 131 億美元。預計從 2026 年到 2033 年，其複合年成長率將達到 9.5%。

報告範圍		報告詳情
基準年：	2025	2026年市場規模：	69億美元
歷史數據時期：	2020年至2024年	預測期：	2026年至2033年
2026年至2033年預測期間的複合年成長率：	9.50%	2033年市場規模預測：	131億美元

基因生物標記是指與生理、免疫或治療反應相關的DNA或RNA特徵。基因生物標記揭示基因表現、功能和調控。作為基因生物標記的DNA特徵包括DNA修飾、插入、缺失、細胞遺傳學重排和單核苷酸多態性（SNP）。基於RNA的基因生物標記包括RNA序列、微型RNA水平和RNA加工。基因生物標記具有重要的臨床意義，因為它們可用於診斷。它們有助於監測癌症等疾病的進展，並在指導標靶藥物遞送方面發揮作用。研發的快速進展使研究人員認知到基因生物標記基因生物標記非侵入性臨床診斷工具的優勢。基因生物標記被廣泛用於檢測使個體容易罹患遺傳性高膽固醇症等疾病的單基因突變。

基因生物標記在藥物研發過程中發揮著至關重要的作用，它們能夠識別個體間藥物代謝和毒性的差異。利用這些基因生物標記的特性，可以實現個人化醫療，從而根據個別患者的特定需求而非一般人群的用藥方案來給予適當的藥物劑量。此外，基因生物標記也被應用於多項臨床前和臨床毒性研究中，以更深入地了解藥物不良反應，從而為藥物研發和病患管理提供更優的決策依據。

市場動態

在藥物研發、腫瘤學、循環系統和神經病學領域，基於基因生物標記的臨床試驗日益普及，並有望在預測期內推動市場成長。根據2020年6月發表於《未來科學》（Future Science）的報導，包括基因生物標記的生物標記在新藥研發中發揮著至關重要的作用，因此也是早期臨床試驗的重要組成部分。此外，2019年，桑尼布魯克健康科學中心啟動了一項臨床試驗，旨在尋找能夠揭示乳癌患者對新輔助化療反應的新型基因生物標記。

市場新進業者正專注於產品上市和獲得核准，這有望鞏固其在全球市場的地位。例如，2020年，總部位於美國的癌症基因組分析公司Personal Genome Diagnostics Inc.獲得了美國食品藥物管理局（FDA）對其PGDx elio tissue complete的批准，這是一款基於基因生物標記的癌症診斷試劑盒。此試劑盒可對所有基因及其交互作用進行全面分析。此類產品獲批數量的不斷增加正在推動基因生物標記市場的成長。

進入市場的公司正努力透過與其他公司和研究機構簽訂授權協議來拓展產品系列。例如，2018年，Personal Genome Diagnostics公司與位於紐約的癌症治療和研究中心－紀念斯隆-凱特琳癌症中心達成協議，共同開發和商業化基於腫瘤突變負荷（TMB）基因生物標記的產品。 TMB是可測量的癌症基因生物標記，用於評估人體對癌症免疫療法的反應。預計這將推動基因生物標記市場的成長。

本次調查的主要特點

本研究揭示了各個細分市場的潛在商機，並為該市場說明了一個具有吸引力的投資提案矩陣。
此外，本研究還深入分析了市場促進因素、限制因素、機會、新產品發布和批准、區域前景以及主要參與者採取的競爭策略。
本研究根據以下參數對全球基因生物標記市場的主要參與者進行了分析：公司概況、財務表現、產品系列、企業發展區域、分銷策略、關鍵發展和策略以及未來計劃。
本報告提供的見解將使企業行銷負責人和經營團隊能夠就未來的產品發布、技術升級、市場擴張和行銷策略做出明智的決策。
這份全球基因生物標記市場報告的目標受群眾外包括行業內的各種相關人員，例如投資者、供應商、製造商、經銷商、新參與企業和金融分析師。
相關人員可以透過利用基因生物標記市場分析中使用的各種策略矩陣來簡化決策過程。

北美洲
- 美國
- 加拿大
拉丁美洲
- 巴西
- 墨西哥
- 阿根廷
- 其他拉丁美洲國家
歐洲
- 英國
- 德國
- 義大利
- 法國
- 西班牙
- 俄羅斯
- 其他歐洲國家
亞太地區
- 中國
- 印度
- 日本
- ASEAN
- 澳洲
- 韓國
- 其他亞太國家
中東
- GCC
- 以色列
- 其他中東國家
非洲
- 北非
- 中非
- 南非

第7章競爭情勢

熱圖分析
市佔率分析
公司簡介
- Thermo Fisher Scientific
- F. Hoffmann-La Roche AG
- Liquid Genomics, Inc.
- AROS Applied Biotechnology A/S
- Myriad Genetics, Inc.
- QIAGEN
- Eurofins Scientific
- Genomic Health
- Bio-Rad Laboratories, Inc.
- Epigenomics AG
- Aepodia
分析師意見

第8章

參考
調查方法
關於本公司

簡介目錄

Product Code: CMI4578

Genomic Biomarker Market is estimated to be valued at USD 6.9 Bn in 2026 and is expected to reach USD 13.1 Bn by 2033, growing at a compound annual growth rate (CAGR) of 9.5% from 2026 to 2033.

Report Coverage		Report Details
Base Year:	2025	Market Size in 2026:	USD 6.9 Bn
Historical Data for:	2020 To 2024	Forecast Period:	2026 To 2033
Forecast Period 2026 to 2033 CAGR:	9.50%	2033 Value Projection:	USD 13.1 Bn

Genomic biomarkers are either DNA or RNA characteristics that are associated with a physiological process, immunological process or therapeutic response. A genomic biomarker reveals the expression, function, and regulation of a gene. DNA characteristics that act as genomic biomarkers include DNA modification, insertions, deletions, cytogenetic rearrangements, single nucleotide polymorphisms (SNPs), and others. Genomic biomarkers based on RNA characteristics comprise of RNA sequence, microRNA levels, RNA processing, etc. Genomic biomarkers are of high clinical significance as these can be used for diagnostic purposes. Genomic biomarkers aid in monitoring the progress of a disease such as cancer and also guide the targeted drug deliveries. Rapid research and development has helped researchers to understand the benefits of genomic biomarkers as a non-invasive clinical diagnostic tool. Genomic biomarkers have been widely used to detect single gene mutations predisposing to disease such as familial hypercholesterolemia disorder.

Genomic biomarkers play a major role in drug development process by identifying differences in drug metabolism and drug toxicity between different individuals. This property of genetic biomarkers can be used to design personalized medicines that will ensure administration of proper dosage of medicine based on the requirement of a particular patient rather than a generalized population. Genomic biomarkers are also used in several preclinical and clinical toxicity studies to have a better understanding of adverse drug reactions, which then helps in making better decisions with regards to drug development and clinical management of patients.

Market Dynamics

Increasing adoption of genomic biomarkers-based clinical trials in drug development, oncology, cardiology, and neurology could contribute to the growth of the market over the forecast period. According to an article published by Future Science in June 2020, biomarkers such as genomic biomarkers play a crucial role in development of novel drugs and are therefore a part of early-phase clinical trials. Moreover, in 2019, Sunnybrook Health Sciences Centre initiated a clinical trial study to identify new genomic biomarkers that would reveal response to neoadjuvant chemotherapy in breast cancer patients.

Market players are focusing on launch of products and approvals, which is expected to strengthen their position in the global market. For instance, in 2020, Personal Genome Diagnostics Inc., an American cancer genome analysis company, received U.S. Food and Drug Administration (FDA) clearance for its product PGDx elio tissue complete, which is a genomic biomarker-based cancer diagnostic kit. This kit involves an extensive analysis of all the genes and their interactions with each other. Rising approvals for such products drive the market growth of genomic biomarkers.

Market players are involved in expanding their product portfolio by entering into licensing agreements with other companies or research organizations. For instance, in 2018, Personal Genome Diagnostics Inc. signed an agreement with Memorial Sloan Kettering Cancer Center, a New York based cancer treatment and research center, for development and commercialization of products under tumor mutation burden (TMB) genomic biomarker status. TMB is a genomic biomarker, which can be measured to determine body's response to cancer immunotherapy. This is expected to drive the growth of the genomic biomarker market.

Key features of the study

It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrix for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, regional outlook, and competitive strategies adopted by the leading players
It profiles leading players in the global genomic biomarker market based on the following parameters - company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments and strategies, and future plans
Key companies covered as a part of this study include Thermo Fisher Scientific, F. Hoffmann-La Roche AG, Liquid Genomics, Inc., AROS Applied Biotechnology A/S, Myriad Genetics, Inc., QIAGEN, Eurofins Scientific, Genomic Health, Bio-Rad Laboratories, Inc., Epigenomics AG, and Aepodia
Insights from this report would allow marketers and the management authorities of the companies to make informed decision regarding their future product launch, technology up-gradation, market expansion, and marketing tactics
The global genomic biomarker market report caters to various stakeholders in this industry including investors, suppliers, manufacturers, distributors, new entrants, and financial analysts
Stakeholders would have ease in decision making through various strategy matrices used in analyzing the genomic biomarker market

Market Segmentation

By Indication (Revenue, USD Bn, 2021-2033)
Oncology
Cardiovascular diseases
Neurological diseases
Others
By End User (Revenue, USD Bn, 2021-2033)
Hospitals
Diagnostic & Research Laboratories
Others
By Region (Revenue, USD Bn, 2021-2033)
North America
- U.S.
- Canada
Latin America
- Brazil
- Mexico
- Argentina
- Rest of Latin America
Europe
- Germany
- U.K.
- France
- Italy
- Spain
- Russia
- Rest of Europe
Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
Middle East
- GCC
- Israel
- Rest of Middle East
Africa
- South Africa
- Central Africa
- North Africa
Key Players
Thermo Fisher Scientific
Hoffmann-La Roche AG
Liquid Genomics, Inc.
AROS Applied Biotechnology A/S
Myriad Genetics, Inc.
QIAGEN
Eurofins Scientific
Genomic Health
Bio-Rad Laboratories, Inc.
Epigenomics AG
Aepodia

1. Research Objectives and Assumptions

Research Objectives
Assumptions
Abbreviations

2. Market Purview

Report Description
- Market Definition and Scope
Executive Summary
- Market Snapshot, By Indication
- Market Snapshot, By End User
- Market Snapshot, By Region
Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

Market Dynamics
- Drivers
- Restraints
- Market Opportunities
Impact Analysis
Market Trends
Key Developments
Product Approval
Collaboration/Merge/Acquisition
Regulatory Landscape
PEST Analysis
Porter's Five Forces Analysis
Epidemiology
Robust Pipeline Analysis

4. Global Genomic Biomarker Market, By Indication, 2021 - 2033, (USD Billion)

Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022- 2033
- Segment Trends
Oncology
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Billion)
Cardiovascular diseases
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Billion)
Neurological diseases
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Billion)
Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Billion)

5. Global Genomic Biomarker Market, By End User, 2021 - 2033, (USD Billion)

Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
Hospitals
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Billion)
Diagnostic & Research Laboratories
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Billion)
Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Billion)

6. Global Genomic Biomarker Market, By Region, 2021 - 2033, (USD Billion)

Introduction
- Market Share Analysis, By Region, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, For Regions, 2022-2033
- Regional Trends
North America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Indication, 2021 - 2033, (USD Billion)
- Market Size and Forecast, and Y-o-Y Growth, By End User, 2021 - 2033, (USD Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033, (USD Billion)
  - U.S.
  - Canada
Latin America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Indication, 2021 - 2033, (USD Billion)
- Market Size and Forecast, and Y-o-Y Growth, By End User, 2021 - 2033, (USD Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033, (USD Billion)
  - Brazil
  - Mexico
  - Argentina
  - Rest of Latin America
Europe
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Indication, 2021 - 2033, (USD Billion)
- Market Size and Forecast, and Y-o-Y Growth, By End User, 2021 - 2033, (USD Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033, (USD Billion)
  - U.K.
  - Germany
  - Italy
  - France
  - Spain
  - Russia
  - Rest of Europe
Asia Pacific
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Indication, 2021 - 2033, (USD Billion)
- Market Size and Forecast, and Y-o-Y Growth, By End User, 2021 - 2033, (USD Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033, (USD Billion)
  - China
  - India
  - Japan
  - ASEAN
  - Australia
  - South Korea
  - Rest of Asia Pacific
Middle East
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Indication, 2021 - 2033, (USD Billion)
- Market Size and Forecast, and Y-o-Y Growth, By End User, 2021 - 2033, (USD Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033, (USD Billion)
  - GCC
  - Israel
  - Rest of Middle East
Africa
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Indication, 2021 - 2033, (USD Billion)
- Market Size and Forecast, and Y-o-Y Growth, By End User, 2021 - 2033, (USD Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033, (USD Billion)
  - North Africa
  - Central Africa
  - South Africa

7. Competitive Landscape

Heat Map Analysis
Market Share Analysis
Company Profile
- Thermo Fisher Scientific
  - Company Highlights
  - Product Portfolio
  - Financial Performance
  - Recent Highlights
  - Market Strategies
- F. Hoffmann-La Roche AG
  - Company Highlights
  - Product Portfolio
  - Financial Performance
  - Recent Highlights
  - Market Strategies
- Liquid Genomics, Inc.
  - Company Highlights
  - Product Portfolio
  - Financial Performance
  - Recent Highlights
  - Market Strategies
- AROS Applied Biotechnology A/S
  - Company Highlights
  - Product Portfolio
  - Financial Performance
  - Recent Highlights
  - Market Strategies
- Myriad Genetics, Inc.
  - Company Highlights
  - Product Portfolio
  - Financial Performance
  - Recent Highlights
  - Market Strategies
- QIAGEN
  - Company Highlights
  - Product Portfolio
  - Financial Performance
  - Recent Highlights
  - Market Strategies
- Eurofins Scientific
  - Company Highlights
  - Product Portfolio
  - Financial Performance
  - Recent Highlights
  - Market Strategies
- Genomic Health
  - Company Highlights
  - Product Portfolio
  - Financial Performance
  - Recent Highlights
  - Market Strategies
- Bio-Rad Laboratories, Inc.
  - Company Highlights
  - Product Portfolio
  - Financial Performance
  - Recent Highlights
  - Market Strategies
- Epigenomics AG
  - Company Highlights
  - Product Portfolio
  - Financial Performance
  - Recent Highlights
  - Market Strategies
- Aepodia
  - Company Highlights
  - Product Portfolio
  - Financial Performance
  - Recent Highlights
  - Market Strategies
Analyst Views